From GlobeNewswire:



Vera Therapeutics, Inc. announced that their management team will present at the 42nd Annual J.P. Morgan Healthcare Conference from January 7 – 11, 2024. Investors can access a replay of the event for 90 days by visiting the “Investor Calendar” section of the Vera Therapeutics website. Vera is currently working on several treatments for serious immunological diseases. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly to treat certain autoimmune diseases, including IgAN and lupus nephritis. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant.

The company retains all global developmental and commercial rights to atacicept and MAU868. The company is focused on advancing treatments that target the source of immunologic diseases. This is in order to change the standard of care for patients. Vera Therapeutics seems to be on the right path to accomplish this mission. If their products continue to prove useful medically, it could lead to significant advancements in treating these diseases.



Read more: Vera Therapeutics to Participate in the 42nd Annual J.P.